Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Requirements
  • ‘Skinny Labeling’
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

TRENDING TOPICS:

  • Medicaid Work Requirements
  • 'Skinny Labeling'
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, May 23 2025

Full Issue

Trying To Win More GLP-1 Patients, Novo Nordisk Looks To Telehealth

Stat reports on the unlikely collaboration between telehealth providers and manufacturers. Other health industry news is on the rising popularity of fractional chief financial officers, and the sentencing of a former senior partner at McKinsey & Company regarding OxyContin sales.

Stat: Ro, LifeMD Promote Novo Nordisk GLP-1 Drug Wegovy At Discount

Eli Lilly and Novo Nordisk have waged war on telehealth companies marketing compounded versions of their blockbuster diabetes and obesity medications. With shortages of the branded drugs declared over, and the window for compounding copies closed, though, some virtual care companies are emerging as unlikely allies. (Palmer, 5/23)

Modern Healthcare: Fractional CFOs Gain Popularity With The Healthcare Sector

Healthcare companies are seeking a more adaptable option for financial expertise without the burden of funding a full-time executive. These executives, called fractional chief financial officers, can provide certain companies with top-tier financial leadership on a part-time basis to help navigate a swath of operational challenges including rising prices, staff burnout and federal policy shifts. (Hudson, 5/22)

The New York Times: Ex-McKinsey Partner Sentenced In Obstruction Case

A former senior partner at McKinsey & Company was sentenced on Thursday to six months in prison for destroying records that shed light on the firm’s role in the national opioid crisis. The partner, Martin Elling, 60, had pleaded guilty to obstruction of justice as part of a federal case against the firm and its efforts to “turbocharge” sales of OxyContin during an overdose epidemic that had already killed hundreds of thousands of people. McKinsey agreed to pay $650 million to end that investigation last December. (Forsythe, 5/22)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF